TB-500, explained
How a synthetic peptide relates to thymosin beta-4, a protein found in nearly every cell — what researchers have studied about cell movement, and what remains unproven in people.
TB-500 is a synthetic peptide related to thymosin beta-4, a small protein found in nearly every human cell. It is often discussed alongside BPC-157, and like BPC-157 its research record is mostly preclinical. This guide covers what TB-500 is, how it relates to thymosin beta-4, what has been studied, and what remains unknown.
What TB-500 is
Thymosin beta-4 is a naturally occurring protein of 43 amino acids. One of its best-understood jobs is binding actin, a structural protein that cells use to hold their shape and to move. Because cell movement is part of how tissue responds to injury, thymosin beta-4 has drawn research interest for decades.
TB-500 is the name used for synthetic material based on thymosin beta-4. The name is used loosely: in the research literature it most often refers to a short fragment containing the protein's actin-binding region, while elsewhere it is sometimes applied to the full-length molecule. That ambiguity is a practical reason to care about where a product comes from and how it is documented.
What researchers have studied
Thymosin beta-4 has been studied in cell and animal models of wound repair and of heart and nervous-system injury. In people, an eye-drop formulation of the full-length protein has been tested in clinical trials for conditions affecting the surface of the eye. Those trials involved the full-length protein applied to the eye, not TB-500, and no thymosin beta-4 product has received FDA approval.
Proposed mechanisms center on cell migration: by interacting with actin, the peptide may influence how readily cells move into an injured area. Laboratory models have also examined blood-vessel formation and inflammatory signaling. These are observations about experimental systems — hypotheses about mechanism, not demonstrations of a benefit in people.
Where the evidence stops
For TB-500 itself, published human data are sparse. Much of what is said about it is extrapolated from studies of full-length thymosin beta-4 or from animal work. There are no large, controlled clinical trials establishing that TB-500 is safe or effective for any condition, and its long-term safety has not been characterized.
What a prescribed protocol looks like
The form, the amount, the schedule and the duration of any protocol are decisions made by the prescribing provider for the individual patient. Nothing in this article should be read as a dosing recommendation. If a source online offers you TB-500 without a licensed provider and a real evaluation involved, treat that as a warning sign, not a shortcut.
FDA status and compounding: what to know
The regulatory picture here deserves precision. TB-500 is not an FDA-approved medication: no product containing it has been approved by the FDA for any use. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety or efficacy.
In July 2026, an FDA advisory committee reviewed whether TB-500 should be added to the list of substances that pharmacies may use in compounding. That review concerns what licensed pharmacies may prepare on a valid prescription. It is not an FDA approval, and it does not establish that TB-500 is safe or effective for any use.
TB-500 is not yet available through Peptivik. If and when it is offered, it will be by prescription only, after an evaluation by a licensed provider, and prepared for individual patients by state-licensed US compounding pharmacies — a different regulatory lane than FDA premarket review, and one you should expect any honest platform to disclose plainly.
If you compete in a tested sport
Thymosin beta-4 and its derivatives, including TB-500, appear on the World Anti-Doping Agency's Prohibited List, which applies to athletes in sports that follow the WADA code. If you are subject to drug testing, check your sport's current rules before considering it.
Questions worth asking a provider
- What the human evidence does and does not show for the reason you are considering it.
- Which molecule the product actually contains — the short fragment or the full-length protein — and how that is documented.
- What is known, and what is not known, about side effects and long-term safety.
- What they would want to evaluate first, and what would lead them to advise against it.
The bottom line
TB-500 is a synthetic peptide based on thymosin beta-4, a protein involved in how cells move. Most of the research is in cells and animals, and human data for TB-500 itself are sparse. It is not FDA-approved for any use. Whether it is appropriate for you is a decision that belongs with a licensed provider who can weigh that limited evidence against your health history.
This content is educational and not a substitute for advice from your provider.